Monoclonal Antibodies to C6 and C5b‑9

Biomaterial Description

These monoclonal antibodies target two critical components of the complement terminal pathway—C6 and the assembled C5b‑9 membrane attack complex (MAC)—providing precise tools for modulating and detecting complement‑mediated injury. Antibodies to C6 prevent MAC formation by blocking assembly at the C5b‑6 stage, enabling researchers to experimentally inhibit complement‑driven tissue damage. Antibodies to C5b‑9 bind the fully formed MAC on cell membranes, allowing sensitive visualization and quantification of complement deposition in disease models.

Across experimental nephropathy and endothelial injury studies, C6 depletion has been shown to reduce proteinuria, while C5b‑9 deposition has been identified as the direct mediator of renal microvascular injury. These antibodies therefore offer both mechanistic insight and functional leverage for studying complement‑dependent pathology in renal and vascular systems.

Applications

-Studying complement‑mediated renal injury by manipulating or detecting MAC activity in models of proteinuria, membranous nephropathy, and endothelial damage

-In vivo inhibition of MAC formation using anti‑C6 antibodies to assess downstream functional and pathological outcomes

-Detection and quantification of MAC deposition using anti‑C5b‑9 antibodies to localize complement attack on glomerular or vascular surfaces

-Validating complement‑targeted therapeutics by selectively blocking or visualizing MAC formation in preclinical models

-Modeling microvascular injury and assessing endothelial susceptibility to complement activation in renal and systemic vascular beds

Advantages

-Direct targeting of MAC components enables precise control of complement terminal pathway activity

-Functional relevance demonstrated in vivo, including reduced proteinuria following C6 depletion

-Specific detection of pathogenic complement deposition through high‑affinity anti‑C5b‑9 binding

-Compatibility with multiple assay formats, including immunohistochemistry, immunofluorescence, Western blotting, and functional inhibition studies

-Suitable for both mechanistic research and translational evaluation of complement‑directed therapies

Distributor Information

Non-Exclusive License available.